Prostate Cancer :: New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.